SAT0387 "do not do" recommendations in the management of comorbidity in patients with axial spondyloarthritis. gecoax project. (15th June 2017)

• Record Type: Journal Article
• Authors: Torre-Alonso, JC; González, C; Castañeda, S; Curbelo, R; Collantes, E; Hernández, MV; Urruticoechea-Arana, A; Nieto, JC; García, J; Abad, MΆ; Ramírez, J; Suárez, C; Dalmau, R; Martín-Arranz, MD; Leόn, L; Hermosa, JC; Obaya, JC; Otόn, T; Carmona, L
• Is Part Of: Annals of the rheumatic diseases. Volume 76(2017)Supplement 2
• Page Start: 918
• Page End: 918
• Publication Date: 2017-06-15
• Subjects: Rheumatism -- Periodicals; 616.723005
• DOI: 10.1136/annrheumdis-2017-eular.5029
• Languages: English
• ISSNs: 0003-4967

Abstract

Abstract : Background: During the development of recommendations and implementation aids of the GECOAx project, the importance of avoiding certain situations was highlighted. Objectives: To recognize what prescriptions, risk assessments, or preventive strategies are wrong practices and should thus be avoided in clinical practice. To establish not to do recommendations in the management of the comorbidity of AxSpA. Methods: A multidisciplinary group was selected [10 rheumatologists, 1 internist, 1 cardiologist, 1 gastroenterologist, 1 psychologist and 2 family physicians]. With the support of 3 methodologists, and after interactions aimed to edit a document for the management of comorbidity launched by the same panel, a list of Not to do recommendations was issued. In a discussion meeting, evidence was provided to support the recommendations, items without sufficient basis were removed, and the final list was produced. Results: A summary list of Not to do recommendations (Table 1) was issued. Conclusions: These recommendations aim to avoid making common mistakes in clinical practice and to help better management of frequent comorbidity in patients with AxSpA. Acknowledgements: This project was funded by Merck Sharp & Dohme Spain. Merck Sharp & Dohme had no influence on either the development of the project or the final content of the manuscript. Disclosure of Interest: None declared